A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy.

Area of Science:

• Immunotherapy
• Oncology
• Molecular Biology

Background:

• Chimeric antigen receptor (CAR) T-cell therapy is a successful cancer treatment for hematological malignancies.
• CAR T-cell therapy carries safety concerns due to potential CAR transgene integration, leading to secondary primary malignancies.
• Existing CAR T-cell therapies involve permanent genetic modification of T-cells.

Purpose of the Study:

• To develop a nonviral, non-integrating method for generating transient CAR T-cells using mRNA.
• To create HER2-targeted CAR T-cells for potential therapeutic applications.
• To provide a detailed protocol for small-scale transient CAR T-cell generation for research and clinical studies.

Main Methods:

• Modified mRNA encoding a HER2-specific CAR was prepared.
• T-cells were electroporated with the CAR mRNA to generate transient CAR T-cells.
• CAR expression, T-cell cytotoxicity, and cytokine secretion (IFN-γ) were analyzed in vitro.

Main Results:

• Efficient surface expression of CAR on T-cells was observed, peaking by day 2 and declining by day 5 post-electroporation.
• Transient HER2-CAR T-cells demonstrated potent cytotoxicity against HER2-positive ovarian cancer cells (SKOV-3).
• High levels of IFN-γ secretion were detected from the transient CAR T-cells.

Conclusions:

• This mRNA-based method provides a safe, transient CAR T-cell generation strategy without permanent transgene integration.
• The protocol is suitable for generating CAR T-cells for preclinical and clinical research, addressing safety concerns associated with integrating CAR T-cell therapies.
• Transient CAR T-cells show promising efficacy against HER2-positive cancers, offering a potentially safer alternative for cancer immunotherapy.